Pulmonary Arterial Hypertension

Researchers determined the feasibility and benefits of switching from PDE5i therapy to riociguat in patients with PAH who fail PDE5i therapy.

The FDA has approved the first treatment option in the United States for patients age 3 years or older with congenital or idiopathic pulmonary arterial hypertension.

A recent study investigated pharmacokinetic interactions between phosphodiesterase type 5 inhibitors and endothelin receptor antagonists used in combination for the treatment of pulmonary arterial...

Pulmonary arterial hypertension can be associated with exposure to certain drugs, such as anorectic agents or selective serotonin reuptake inhibitors.

Ambrisentan may be an effective adjunctive therapy for patients with pulmonary arterial hypertension who inadequately respond to PDE5i monotherapy.

Researchers sought to determine if any serological biomarkers for PAH could be identified in patients with systemic lupus erythematosus.

A recent study evaluated the efficacy of magnetic resonance imaging measurements for assessing potential outcomes in patients with pulmonary arterial hypertension.

The relationship between elevated plasma endothelin-1 levels and pulmonary hypertension, mortality, and heart failure was assessed in a recent study.